Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
LB-100 by Lixte Biotechnology for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
LB-100 is under clinical development by Lixte Biotechnology and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to...
LB-100 by Lixte Biotechnology for Soft Tissue Sarcoma: Likelihood of Approval
LB-100 is under clinical development by Lixte Biotechnology and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData,...
LB-100 by Lixte Biotechnology for Nerve Sheath Tumor: Likelihood of Approval
LB-100 is under clinical development by Lixte Biotechnology and currently in Phase II for Nerve Sheath Tumor. According to GlobalData,...
LB-100 by Lixte Biotechnology for Leiomyosarcoma: Likelihood of Approval
LB-100 is under clinical development by Lixte Biotechnology and currently in Phase II for Leiomyosarcoma. According to GlobalData, Phase II...
LB-100 by Lixte Biotechnology for Myxoid Liposarcoma: Likelihood of Approval
LB-100 is under clinical development by Lixte Biotechnology and currently in Phase II for Myxoid Liposarcoma. According to GlobalData, Phase...
LB-100 by Lixte Biotechnology for Pleomorphic Liposarcoma: Likelihood of Approval
LB-100 is under clinical development by Lixte Biotechnology and currently in Phase II for Pleomorphic Liposarcoma. According to GlobalData, Phase...
LB-100 by Lixte Biotechnology for Fibrosarcoma: Likelihood of Approval
LB-100 is under clinical development by Lixte Biotechnology and currently in Phase II for Fibrosarcoma. According to GlobalData, Phase II...
LB-100 by Lixte Biotechnology for Synovial Sarcoma: Likelihood of Approval
LB-100 is under clinical development by Lixte Biotechnology and currently in Phase II for Synovial Sarcoma. According to GlobalData, Phase...
LB-100 by Lixte Biotechnology for Myelodysplastic Syndrome: Likelihood of Approval
LB-100 is under clinical development by Lixte Biotechnology and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase...
LB-100 by Lixte Biotechnology for Small-Cell Lung Cancer: Likelihood of Approval
LB-100 is under clinical development by Lixte Biotechnology and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...
LB-100 by Lixte Biotechnology for Peritoneal Cancer: Likelihood of Approval
LB-100 is under clinical development by Lixte Biotechnology and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...
LB-100 by Lixte Biotechnology for Fallopian Tube Cancer: Likelihood of Approval
LB-100 is under clinical development by Lixte Biotechnology and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...
LB-100 by Lixte Biotechnology for Ovarian Cancer: Likelihood of Approval
LB-100 is under clinical development by Lixte Biotechnology and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...